Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

LRRK2

Leucine-rich repeat kinase 2 (LRRK2), also known as dardarin (from the Basque word "dardara" which means trembling) and PARK8 (from early identified association with Parkinson's disease), is a kinase enzyme that in humans is encoded by the LRRK2 gene. LRRK2 is a member of the leucine-rich repeat kinase family. Variants of this gene are associated with an increased risk of Parkinson's disease and also Crohn's disease.

LRRK2-IN-7
T731762307277-93-4In house
LRRK2-IN-7 is a selective, CNS permeable and potent LRRK2 kinase inhibitor (IC50: 0.9 nM) for the study of Parkinson's disease.
  • $239
In Stock
Size
QTY
IKK 16
T6176873225-46-8
IKK 16 (IKK Inhibitor VII) is a selective IκB kinase (IKK) inhibitor for IKK-2, IKK complex and IKK-1 with IC50 of 40 nM, 70 nM and 200 nM, respectively.
  • $34
In Stock
Size
QTY
PFE-360
T165121527475-61-1
PFE-360 (PF-06685360) is a potent and selective inhibitor of LRRK2 kinase, with an in vivo IC50 of 2.3 nM.
  • $68
In Stock
Size
QTY
TargetMol | Inhibitor Sale
MLi-2
T161151627091-47-7
MLi-2 is a structurally novel, highly potent, and selective LRRK2 kinase inhibitor with central nervous system activity. MLi-2 exhibits exceptional potency in a purified LRRK2 kinase assay in vitro (IC50 = 0.76 nM), a cellular assay monitoring dephosphorylation of LRRK2 pSer935 LRRK2 (IC50 = 1.4 nM), and a radioligand competition binding assay (IC50 = 3.4 nM).
  • $60
In Stock
Size
QTY
GNE0877
T60311374828-69-9
GNE0877 (GNE 0877) is a highly effective and specific leucine-rich repeat kinase 2 (LRRK2) inhibitor (Ki: 0.7 nM).
  • $39
In Stock
Size
QTY
TargetMol | Inhibitor Sale
LRRK2 inhibitor 1
T118781802525-61-6In house
LRRK2 inhibitor 1 is a selective and potent LRRK2 inhibitor with an IC50 of 13 nM.LRRK2 inhibitor 1 inhibits DCLK1 kinase with an IC50 value of 2.61 nM.
  • $68
In Stock
Size
QTY
LRRK2-IN-1
T22461234480-84-2
LRRK2-IN-1 is an effective and selective LRRK2 inhibitor.
  • $60
In Stock
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
EB-42486
T399722390475-81-5
EB-42486 is an effective and highly selective inhibitor of G2019S-LRRK2 with an IC50 < 0.2 nM.
  • $64
In Stock
Size
QTY
URMC-099
T60571229582-33-5
URMC-099 is an orally bioavailable, brain penetrant MLK inhibitor (IC50: 19 42 14 150 nM, for MLK1 MLK2 MLK3 DLK), and also inhibits LRRK2 activity (IC50: 11 nM).
  • $52
In Stock
Size
QTY
BIX 02565
T54281311367-27-7In house
BIX 02565 is a potent inhibitor of ribosomal S6 kinase 2 (RSK2, IC50: 1.1 nM).
  • $178
In Stock
Size
QTY
TargetMol | Citations Cited
HG-10-102-01
T71961351758-81-0
HG-10-102-01 is an inhibitor of leucine-rich repeat kinase 2 (LRRK2, IC50 of 20.3 nM).
  • $32
In Stock
Size
QTY
TargetMol | Inhibitor Sale
JH-II-127
T71551700693-08-8
JH-II-127 is an oral inhibitor of leucine-rich repeat kinase 2 (LRRK2), targeting WT LRRK2, G2019S LRRK2, and A2016T LRRK2 with IC50 values of 6.6 nM, 2.2 nM, and 47.7 nM, respectively.
  • $45
In Stock
Size
QTY
TargetMol | Inhibitor Sale
GNE-7915
T19451351761-44-8
GNE-7915 is a highly potent, selective and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) inhibitor.
  • $39
In Stock
Size
QTY
CCG-1423
T2014285986-88-1
CCG-1423, a selective RhoA pathway inhibitor, suppresses SRF-mediated transcription.
  • $32
In Stock
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
CZC-54252
T20221191911-27-9
CZC-54252 is a potent inhibitor of LRRK2.
  • $32
In Stock
Size
QTY
PF-06447475
T20501527473-33-1
PF-06447475 is a highly effective, specific, brain penetrant LRRK2 inhibitor with IC0 of 3 11 nM for wild type LRRK2 and G2019S LRRK2 respectively.
  • $43
In Stock
Size
QTY
TargetMol | Inhibitor Sale
GNE-9605
T17701536200-31-3
GNE-9605 is a highly effective, specifical, and brain-penetrant LRRK2 inhibitor (IC50: 19 nM).
  • $32
In Stock
Size
QTY
TargetMol | Inhibitor Sale
GSK2578215A
T22401285515-21-0
GSK2578215A is a potent and selective LRRK2 kinase inhibitor.
  • $29
In Stock
Size
QTY
PF-06454589
T77291527473-30-8
PF-06454589 is a potent inhibitor of LRRK2.
  • $30
In Stock
Size
QTY
TargetMol | Inhibitor Sale
CZC-25146 hydrochloride
T51391330003-04-7
CZC-25146 is a selective LRRK2 inhibitor with IC50 of 4.76 nM 6.87 nM for wild type LRRK2 and G2019S LRRK2, respectively.
  • $30
In Stock
Size
QTY
TargetMol | Inhibitor Sale
CZC-25146
T30531191911-26-8
CZC-25146 (CHEMBL2397014) is an effective, specific and metabolically stable LRRK2 inhibitor with IC50 of 4.76/6.87 nM for wild-type LRRK2(Leucine-rich repeat kinase-2) and G2019S LRRK2, respectively.
  • $39
In Stock
Size
QTY
TargetMol | Inhibitor Sale
CZC-54252 hydrochloride
T392021784253-05-9
CZC-54252 hydrochloride is a selective inhibitor of LRRK2 with IC50s of 1.85 nM and 1.28 nM for wild-type and G2019S LRRK2. CZC-54252 hydrochloride has a neuroprotective activity and attenuates G2019S LRRK2-induced human neuronal injury with an EC50 of 1 nM.
  • $44
In Stock
Size
QTY
TargetMol | Inhibitor Sale
MK-1468
T817852769107-89-1
MK-1468, a highly selective and brain-penetrant LRRK2 inhibitor, exhibits an IC50 of 0.8 nM and is utilized in the study of Parkinson's disease [1].
  • Inquiry Price
8-10 weeks
Size
QTY
Nictide
TP28371159973-22-4
Nictide, a peptide substrate for LRRK2 (leucine-rich repeat protein kinase-2), undergoes phosphorylation by the activated form of LRRK2[G2019S], exhibiting a Km value of 10 μM.
  • Inquiry Price
Size
QTY
LRRK2-IN-10
T797462704562-80-9
LRRK2-IN-10 (compound 34) is a potent, mutation-selective, brain-penetrant inhibitor targeting G2019S-LRRK2 kinase with IC50 values of 11 nM for G2019S-LRRK2 pS935 and 5.2 nM for G2019S-LRRK2 pS1292, holding promise for research into Parkinson's disease [1].
  • $1,520
6-8 weeks
Size
QTY
LRRK2-IN-15
T200475
LRRK2-IN-15 is an inhibitor of LRRK2. It exhibits an IC50 value of 5 nM in PBMC cells and 1.5 μM for BCRP. This compound is utilized in the research of Parkinson's disease.
  • Inquiry Price
Size
QTY